Zacks Investment Research
12 Jun 2026, 10:45 UTC · 2h ago
Adaptive Biotechnologies (ADPT) Moves 9.7% Higher: Will This Strength Last?
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Zacks Investment Research
12 Jun 2026, 10:45 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
Adaptive Biotechnologies (ADPT) shares rose 9.7% in the last trading session on high volume, following a 30% gain over the past four weeks. — Strong immediate price momentum and volume indicate significant positive sentiment and accumulation by investors.
+0.40Analysts have revised the consensus EPS estimate for Adaptive Biotechnologies (ADPT) 3.6% higher over the last 30 days. — Upward earnings revisions are historically correlated with continued near-term stock price appreciation.
+0.30Adaptive Biotechnologies is expected to report a quarterly revenue increase of 14.2% year-over-year to $67.24 million in its next report. — Double-digit revenue growth supports the bullish thesis regarding the commercial growth of their lead product, clonoSEQ.
+0.20Which stocks this story touches
Continue reading
6 related stories
Top 2 movers · tap to explore
Shares rallied 9.7% following robust financial results and growing investor confidence in its lead product and pipeline.
The stock finished the last trading session 4.4% higher, although it has declined over the past month.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Seeking Alpha
5h ago
